About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/23/2021.
This website is for US healthcare professionals

Log In to Bolder Science


Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/23/2021.

Pre-Approval Access to Golimumab Subcutaneous for the Treatment of Stage 3 Type-1 Diabetes Mellitus in Children and Young Adults

Clinicaltrials.gov identifier NCT03945903

Recruitment Status Available

First Posted May 10, 2019

Last update posted May 13, 2020

Study Description

Brief summary:

This is a Single Patient Investigational New Drug (IND) to golimumab subcutaneous (SC) for the treatment of recently diagnosed Stage 3 type-1 diabetes mellitus (T1D) in children and young adults. The main purpose of a single patient IND is to provide treatment to participants with serious/life-threatening diseases or conditions prior to marketing authorization.

  • Condition or Disease:Diabetes Mellitus, Type 1
  • Intervention/Treatment: Drug: Golimumab
  • Phase: N/A
Detailed Description


Study Design
  • Study Type: Expanded Access
  • Official Title: SIMPONI SC Managed Access Program
  • Study Start Date: N/A
  • Primary Completion Date: N/A
  • Study Completion Date: N/A
Outcome Measures
Eligibility Criteria
  • Ages Eligible for Study: (Child, Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers:

Inclusion Criteria:


Exclusion Criteria:


Contacts and Locations

Contact: Study Contact 1-800-JANSSEN (1-800-526-7736) Janssenmedinfo@its.jnj.com


United States, California
Rady Children's Hospital
San Diego

Sponsors and Collaborators

Janssen Research & Development, LLC


Study Director: Janssen Research & Development, LLC Clinical Trial Janssen Research & Development, LLC

More Information
  • Responsible Party: Janssen Research & Development, LLC
  • ClinicalTrials.gov Identifier: NCT03945903 History of Changes
  • Other Study ID Numbers: CR108621, CNTO148DML4001
  • First Posted: May 10, 2019 Key Record Dates
  • Last Update Posted: May 13, 2020
  • Last Verified: May 2020
  • Additional relevant MeSH terms: Diabetes Mellitus Diabetes Mellitus, Type 1